These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 20878094)

  • 1. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
    Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
    Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
    Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
    Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A
    Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
    Kong A; Calleja V; Leboucher P; Harris A; Parker PJ; Larijani B
    PLoS One; 2008 Aug; 3(8):e2881. PubMed ID: 18682844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
    Meng X; Li Y; Tang H; Mao W; Yang H; Wang X; Ding X; Xie S
    Amino Acids; 2016 Feb; 48(2):487-97. PubMed ID: 26439378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
    Evans AH; Pancholi S; Farmer I; Thornhill A; Evans DB; Johnston SR; Dowsett M; Martin LA
    Br J Cancer; 2010 Apr; 102(8):1235-43. PubMed ID: 20386540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
    Younes MN; Park YW; Yazici YD; Gu M; Santillan AA; Nong X; Kim S; Jasser SA; El-Naggar AK; Myers JN
    Mol Cancer Ther; 2006 Nov; 5(11):2696-705. PubMed ID: 17121916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
    Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Anti-EGFR/anti- HER2 Bispecific Antibody with Enhanced Antitumor Activity Against Acquired Gefitinib-Resistant NSCLC Cells.
    Si Y; Pei X; Wang X; Han Q; Xu C; Zhang B
    Protein Pept Lett; 2021; 28(11):1290-1297. PubMed ID: 34602035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
    Borrero-García LD; Del Mar Maldonado M; Medina-Velázquez J; Troche-Torres AL; Velazquez L; Grafals-Ruiz N; Dharmawardhane S
    BMC Cancer; 2021 Jun; 21(1):652. PubMed ID: 34074257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
    Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
    Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 expression as a potential marker for response to therapy targeted to the EGFR.
    Emlet DR; Schwartz R; Brown KA; Pollice AA; Smith CA; Shackney SE
    Br J Cancer; 2006 Apr; 94(8):1144-53. PubMed ID: 16622439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
    Goudar RK; Shi Q; Hjelmeland MD; Keir ST; McLendon RE; Wikstrand CJ; Reese ED; Conrad CA; Traxler P; Lane HA; Reardon DA; Cavenee WK; Wang XF; Bigner DD; Friedman HS; Rich JN
    Mol Cancer Ther; 2005 Jan; 4(1):101-12. PubMed ID: 15657358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.